Publication | Closed Access
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
373
Citations
26
References
2010
Year
Sorafenib is reasonably well tolerated, with suggestion of clinical benefit for patients with sporadic MTC. Caution should be taken because of the rare but fatal toxicity potentially associated with sorafenib.
| Year | Citations | |
|---|---|---|
Page 1
Page 1